See more : Golden Entertainment, Inc. (GDEN) Income Statement Analysis – Financial Results
Complete financial analysis of GT Biopharma, Inc. (GTBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GT Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Simbhaoli Sugars Limited (SIMBHALS.BO) Income Statement Analysis – Financial Results
- Mito Securities Co., Ltd. (8622.T) Income Statement Analysis – Financial Results
- Rare Earth Magnesium Technology Group Holdings Limited (0601.HK) Income Statement Analysis – Financial Results
- Williamson Magor & Co. Limited (WILLAMAGOR.BO) Income Statement Analysis – Financial Results
- Adagio Therapeutics, Inc. (ADGI) Income Statement Analysis – Financial Results
GT Biopharma, Inc. (GTBP)
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.00K | 61.00K | 368.00K | 342.00K | 26.00K | 11.00K | 48.00K | 1.14M | 6.05M | 5.78M | 2.50M | 2.36M | 2.74M | 2.05M | 2.97M | 3.54M | 7.17M | 5.10M | 5.10M | 4.90M | 5.10M | 3.50M | 3.00M | 2.80M | 2.70M | 4.80M | 5.10M | 3.20M | 2.30M | 3.00M | 2.40M | 4.16M | 3.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 57.00K | 226.00K | 94.00K | 48.00K | 65.00K | 50.00K | 909.00K | 3.26M | 3.08M | 1.35M | 1.22M | 1.50M | 1.14M | 2.43M | 2.62M | 5.05M | 2.60M | 2.00M | 1.60M | 1.60M | 1.50M | 1.20M | 1.20M | 1.00M | 1.90M | 2.10M | 1.20M | 500.00K | 1.10M | 900.00K | 2.33M | 2.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.00K | -7.00K | -2.00K | -1.00K | 25.00K | 4.00K | 142.00K | 248.00K | -22.00K | -54.00K | -2.00K | 234.00K | 2.79M | 2.69M | 1.15M | 1.15M | 1.24M | 910.00K | 538.00K | 924.00K | 2.11M | 2.50M | 3.10M | 3.30M | 3.50M | 2.00M | 1.80M | 1.60M | 1.70M | 2.90M | 3.00M | 2.00M | 1.80M | 1.90M | 1.50M | 1.83M | 1.55M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.59% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | -4.17% | 20.47% | 46.09% | 46.61% | 46.14% | 48.56% | 45.40% | 44.39% | 18.13% | 26.10% | 29.50% | 49.02% | 60.78% | 67.35% | 68.63% | 57.14% | 60.00% | 57.14% | 62.96% | 60.42% | 58.82% | 62.50% | 78.26% | 63.33% | 62.50% | 43.99% | 40.47% |
| Research & Development | 6.47M | 8.81M | 9.59M | 485.00K | 1.67M | 9.07M | 1.07M | 975.00K | 1.00M | 0.00 | 0.00 | 0.00 | 17.00K | 179.00K | 0.00 | 44.00K | 1.04M | 708.00K | 499.00K | 236.00K | 369.00K | 463.00K | 762.00K | 1.91M | 2.40M | 4.40M | 4.30M | 4.90M | 4.30M | 1.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 400.00K |
| General & Administrative | 0.00 | 0.00 | 47.92M | 6.28M | 9.79M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 935.00K | 3.36M | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.11M | 12.45M | 47.92M | 6.28M | 9.79M | 12.49M | 134.50M | 8.40M | 7.95M | 2.40M | 935.00K | 3.76M | 3.89M | 2.26M | 1.15M | 1.40M | 2.87M | 4.65M | 2.34M | 2.03M | 1.65M | 1.26M | 2.29M | 3.30M | 3.29M | 3.60M | 2.60M | 2.80M | 3.30M | 1.70M | 3.40M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.13M | 1.19M |
| Other Expenses | 0.00 | 0.00 | -242.76K | -12.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00K | 0.00 | 0.00 | 0.00 | 942.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.40M | 935.00K | 3.76M | 3.91M | 2.44M | 1.15M | 1.45M | 3.90M | 5.36M | 2.84M | 2.26M | 2.02M | 1.72M | 3.99M | 5.65M | 6.52M | 9.60M | 8.10M | 9.10M | 9.00M | 4.00M | 3.50M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.72M | 1.60M |
| Cost & Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.46M | 1.16M | 3.86M | 3.95M | 2.51M | 1.20M | 2.35M | 7.17M | 8.45M | 4.19M | 3.48M | 3.51M | 2.86M | 6.42M | 8.27M | 11.58M | 12.20M | 10.10M | 10.70M | 10.60M | 5.50M | 4.70M | 3.30M | 3.20M | 4.30M | 4.60M | 3.30M | 2.10M | 3.60M | 3.20M | 4.05M | 3.88M |
| Interest Income | 567.00K | 292.00K | 38.00K | 3.32K | 2.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 52.00K | 80.00K | 110.00K | 1.00K | 1.00K | 7.00K | 29.00K | 180.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.00K | 718.00K | 3.32M | 2.13M | 9.12M | 8.60M | 6.56M | 17.04M | 5.15M | 1.20M | 1.65M | 556.00K | 513.00K | 1.14M | 1.66M | 1.01M | 2.16M | 26.00K | 101.00K | 14.00K | 18.00K | 14.00K | 90.00K | 0.00 | 300.00K | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.00K | 210.00K |
| Depreciation & Amortization | 13.58M | 21.26M | 57.52M | 4.00K | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 22.00K | 2.00K | 3.00K | 23.00K | 31.00K | 55.00K | 251.00K | 893.00K | 301.00K | 154.00K | 785.00K | 177.00K | 282.00K | 412.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | -300.00K | -300.00K | -300.00K | -300.00K | -200.00K | 100.00K | -200.00K | -300.00K | 790.00K | 480.00K |
| EBITDA | 5.98M | 0.00 | 0.00 | -24.98M | -11.45M | -250.06M | -135.57M | -9.37M | -8.93M | -2.37M | -791.00K | -3.61M | -3.12M | -2.45M | -1.06M | -822.00K | -223.00K | -2.37M | -1.54M | -1.72M | -596.00K | -529.00K | -3.04M | -4.28M | -3.57M | -5.50M | -3.80M | -4.50M | -4.10M | -1.40M | -1.60M | -800.00K | -800.00K | 200.00K | 200.00K | -300.00K | 200.00K | -800.00K | -1.10M | 890.00K | 430.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,055.56% | -3,891.80% | -602.17% | -1,026.61% | -15,019.23% | -22,418.18% | -2,285.42% | -83.99% | -48.64% | -42.64% | -1.56% | 47.08% | -22.04% | -25.80% | -68.80% | -120.99% | -50.65% | -113.73% | -76.47% | -89.80% | -15.69% | 62.86% | -60.00% | -28.57% | -29.63% | 4.17% | 3.92% | -9.38% | 13.04% | -26.67% | -45.83% | 21.39% | 11.23% |
| Operating Income | -13.58M | -21.26M | -57.52M | -6.76M | -16.06M | -250.07M | -135.57M | -9.37M | -8.93M | -2.40M | -793.00K | -3.51M | -3.93M | -2.50M | -1.16M | -1.21M | -1.12M | -2.67M | -3.19M | -1.72M | -773.00K | -811.00K | -3.45M | -4.73M | -4.41M | -7.10M | -5.00M | -5.80M | -5.50M | -2.00M | -1.70M | -500.00K | -500.00K | 500.00K | 500.00K | -100.00K | 200.00K | -600.00K | -800.00K | 100.00K | -50.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,062.96% | -3,927.87% | -215.49% | -1,027.49% | -15,107.69% | -22,700.00% | -2,408.33% | -105.95% | -18.45% | -46.23% | -127.71% | -72.72% | -28.21% | -39.56% | -116.34% | -133.50% | -61.55% | -139.22% | -98.04% | -118.37% | -107.84% | -57.14% | -56.67% | -17.86% | -18.52% | 10.42% | 9.80% | -3.13% | 8.70% | -20.00% | -33.33% | 2.40% | -1.31% |
| Total Other Income/Expenses | 5.98M | 373.00K | -498.00K | -21.53M | -22.59M | -9.12M | -7.68M | 19.14M | -12.53M | -21.11M | 229.00K | -1.75M | 228.00K | -498.00K | -1.09M | -1.50M | 1.49M | -1.98M | 82.00K | -937.00K | -5.00K | -11.00K | -999.00K | 0.00 | 57.00K | 300.00K | 100.00K | 0.00 | -3.30M | -3.60M | 200.00K | 300.00K | 300.00K | 300.00K | 300.00K | 200.00K | 200.00K | 200.00K | 300.00K | 290.00K | 210.00K |
| Income Before Tax | -7.60M | -20.88M | -58.01M | -28.30M | -38.65M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -564.00K | -5.26M | -3.70M | -3.00M | -2.25M | -2.71M | 546.00K | 4.82M | -3.11M | -2.66M | -778.00K | -822.00K | -4.45M | 0.00 | -4.35M | -6.80M | -4.90M | 0.00 | -8.80M | -5.60M | -1.50M | -200.00K | -200.00K | 800.00K | 800.00K | 100.00K | 400.00K | -400.00K | -500.00K | 390.00K | 160.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -153.26% | -1,538.30% | -14,230.77% | -27,227.27% | -4,679.17% | -237.01% | 9.03% | 83.45% | -124.43% | -112.35% | -28.39% | -40.10% | -150.00% | 0.00% | -60.75% | -133.33% | -96.08% | 0.00% | -172.55% | -160.00% | -50.00% | -7.14% | -7.41% | 16.67% | 15.69% | 3.13% | 17.39% | -13.33% | -20.83% | 9.38% | 4.18% |
| Income Tax Expense | 0.00 | -381.00K | 680.00K | 3.32M | 2.13M | -228.52M | 7.68M | -30.41M | 17.04M | 5.15M | -292.00K | 1.56M | 556.00K | 513.00K | 1.14M | 77.00K | 75.00K | 120.00K | 2.00K | 1.54M | 13.00K | 0.00 | 42.00K | -42.00K | 85.00K | 0.00 | 200.00K | 200.00K | 3.40M | 3.60M | -200.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 180.00K | 70.00K |
| Net Income | -7.60M | -20.50M | -58.69M | -31.62M | -40.78M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -501.00K | -5.17M | -3.70M | -3.00M | -2.25M | -5.01M | 471.00K | -4.94M | -3.11M | -2.66M | -791.00K | -822.00K | -3.50M | -4.68M | -4.50M | -7.10M | -5.20M | -6.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 900.00K | 700.00K | 100.00K | 300.00K | -400.00K | -300.00K | 420.00K | 150.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -136.14% | -1,511.99% | -14,230.77% | -27,227.27% | -4,679.17% | -437.97% | 7.79% | -85.53% | -124.51% | -112.35% | -28.87% | -40.10% | -117.76% | -132.32% | -62.74% | -139.22% | -101.96% | -122.45% | -174.51% | -160.00% | -50.00% | -10.71% | -7.41% | 18.75% | 13.73% | 3.13% | 13.04% | -13.33% | -12.50% | 10.10% | 3.92% |
| EPS | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| EPS Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| Weighted Avg Shares Out | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
| Weighted Avg Shares Out (Dil) | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
GT Biopharma Reports Third Quarter 2024 Financial Results
SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced...
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced...
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced...
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company's common stock...
What made GT Biopharma stock more than double on Monday?
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company.
Why Is GT Biopharma (GTBP) Stock Up 143% Today?
GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing.
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first...
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth...
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that...
Source: https://incomestatements.info
Category: Stock Reports